AbbVie: A Dividend Fortress At An Appealing Price Tag

AbbVie earns a buy rating, supported by accelerating top and bottom-line growth and a compelling valuation at 18x forward P/E. ABBV offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Dividend growth remains central to ABBV's shareholder-friendly capital allocation, with a payout ratio of 59% and consensus expectations for continued increases. Despite recent double-digit price gains, ABBV's defensive profile and steady fundamentals make it a strong diversification candidate amid market volatility.

I had AbbVie (ABBV) on my watchlist for a while now, but I was hesitant to initiate coverage. Now, that's about to change because I find several catalysts developing favorably for the biopharma name. Also, it